EXEL — EXELIXIS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 939767 ·
Last close
$68.50
Market Cap
$16.71B
52W High
$73.69
52W Low
$39.71
ADV30
2,792,090
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 658,696,000 | 632,463,000 | 268,423,000 | 218,095,000 | 2,513,489,000 | 304,774,000 | 679,657,000 |
| Jun 2026 | 628,690,000 | 608,033,000 | 248,414,000 | 212,050,000 | 2,494,234,000 | 281,448,000 | 650,472,000 |
| Mar 2026 | 610,812,000 | 590,859,000 | 251,341,000 | 210,467,000 | 2,593,593,000 | 226,152,000 | 657,845,000 |
| Dec 2025 | 598,663,000 | 572,182,000 | 235,910,000 | 244,528,000 | 2,844,423,000 | 482,488,000 | 683,104,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,173,057,000
Investing CF
$60,893,000
Financing CF
$-1,305,476,000
CapEx
$-28,571,000
Dividends Paid
—
Buybacks
$-1,260,907,000
EPS Diluted TTM
$3.34
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-258,802,000
Inventory
$29,871,000
Receivables
$328,466,000
ST Investments
$587,244,000
EBIT TTM
$1,004,088,000
Pretax Income TTM
$1,065,838,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,496,860,928
EBITDA
$1,031,900,992
Free Cash Flow
$761,998,016
Enterprise Value
$16,202,098,688
Total Cash
$892,017,984
Total Debt
$162,200,992
Shares Out
244,010,895
Trailing EPS
$3.34
Book Value
$7.50
ROE
44.3%
ROA
23.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,320,126,000 | 892,701,000 | 782,570,000 | 2,844,423,000 | 683,104,000 | 2,161,319,000 | 884,267,000 |
| Dec 2024 | 2,168,701,000 | 689,949,000 | 521,267,000 | 2,947,690,000 | 703,487,000 | 2,244,203,000 | 699,971,000 |
| Dec 2023 | 1,830,208,000 | 170,885,000 | 207,765,000 | 2,942,357,000 | 678,445,000 | 2,263,912,000 | 333,324,000 |
| Dec 2022 | 1,611,062,000 | 201,484,000 | 182,282,000 | 3,071,489,000 | 583,062,000 | 2,488,427,000 | 362,614,000 |
TTM Snapshot
Revenues TTM
$2,435,920,000
NetIncome TTM
$860,623,000
OpCashFlow TTM
—
Assets (Latest)
$2,494,234,000
Forward EPS
$4.31
Max Pain — expiry 2026-12-18
max pain strike: $50.00 · spot: $68.29 · call oi: 3,938 · put oi: 13,818
Expected Move to 2026-12-18:
±$5.62
(8.24%) —
implied range
$62.67 –
$73.92
· ATM straddle on $67.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.79B | $165.92 | — |
| BNTX | BioNTech SE | $21.32B | $84.86 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
News headlines (Yahoo Finance, 1h cache)
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
2026-11-16 21:52 · Yahoo
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
2026-11-13 12:25 · Yahoo
Forget clinical cash burns: Why Exelixis is up 38% since June
2026-11-12 07:15 · Yahoo
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
2026-11-11 22:12 · Yahoo
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
2026-11-11 05:14 · Yahoo
Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist
2026-11-09 16:35 · Yahoo
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
2026-11-03 21:05 · Yahoo
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
2026-11-02 13:15 · Yahoo
Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
2026-10-31 04:20 · Yahoo
Exelixis (EXEL) Q3 2026 Earnings Call Transcript
2026-10-30 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.